TG Therapeutics Poised for 6.6% Gain as Implied Volatility Hits 6th Percentile
TG Therapeutics has climbed 44% year-to-date and recently broke above an ascending channel off March lows before stalling at a $44 ceiling. Its implied volatility at 46%, in the low 6th percentile, is a bullish setup that preceded average 6.6% gains one month later 75% of the time.
1. Price Performance and Technical Breakout
TG Therapeutics has surged 44% year-to-date and recently broke above an ascending channel formed since mid-March lows, but encountered resistance at the $44 level. The failure to clear this ceiling constrains near-term upside while testing bullish momentum.
2. Volatility Signal and Expected Gains
The stock’s implied volatility is currently 46%, placing it in the low 6th percentile of its annual range. Historically, similar low-volatility setups when near 52-week highs led to an average 6.6% gain one month later in 75% of instances, suggesting potential upside toward $45.
3. Short Interest and Analyst Ratings
Short interest in TG Therapeutics stands at 19.4% of the float, requiring over three weeks of average trading volume to cover bearish positions. Of nine analysts covering the stock, three maintain ‘hold’ or worse ratings, indicating room for bullish revisions.